FAT BURNER
Food supplement declared in France, declaration No 2022-11-1205
FAT BURNER is a food supplement declared in France. Status: earlier declaration, replaced by the 2023 declaration. 2 rules of use apply to its ingredients (limits and warnings).
- Brand
- not provided
- Food business operator placing the product on the market
- Monsieur CERTAIN Cyril
- Status
- Earlier declaration, replaced by the 2023 declaration : FAT BURNER
- Form
- Capsule
- Daily dose
- 4 gélules
- Directions for use
- Prendre 2 gélules 2 fois par jour, à avaler avec un grand verre d'eau, au cours des repas
- Not recommended (according to the manufacturer)
- Adolescents (under 18), Breastfeeding women, Taking away from meals, Children (under 12), Young children (aged 1 to 3), Pregnant women, Infants (under 1 year), Heart problems, Liver problems, Taking diabetes medication, Taking medication, Children (under 6), Children (under 10)
- Objectives stated by the manufacturer (these are not authorised claims)
- Slimming / Fat burner
Declaration 325320, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.
Declared composition
Plants
| Plant | Part | Preparation | Per day |
|---|---|---|---|
| Berberis aristata DC. | Racine | Extrait sec hydroalcoolique | 350 mg |
| Zingiber officinale Roscoe | Racine | Extrait sec hydroalcoolique | 250 mg |
| Ilex paraguariensis A. St.-Hil. | Feuille | Extrait sec hydroalcoolique | 250 mg |
| Paullinia cupana Kunth | Graine | Extrait sec hydroalcoolique | 190 mg |
| Camellia sinensis (L.) Kuntze | Feuille | Extrait sec hydroalcoolique | 150 mg |
| Plectranthus barbatus Andrews | Racine | Extrait sec hydroalcoolique | 125 mg |
| Citrus paradisi Macfad. | Fruit | Extrait sec hydroalcoolique | 100 mg |
| Capsicum annuum L. | Fruit | Extrait sec hydroalcoolique | 80 mg |
| Piper nigrum L. | Fruit | Extrait sec hydroalcoolique | 5 mg |
Other active ingredients
| Name | Per day |
|---|---|
| L-Carnitine L-Tartrate | not declared |
| Tyrosine | not declared |
Additives
E464, E460, E470b, E551
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.
Label warnings
Les compléments alimentaires doivent être utilisés dans le cadre d'un mode de vie sain et ne pas être utilisés en substitution d'un régime alimentaire varié et équilibré.Tenir hors de la portée des jeunes enfants.Ne pas dépasser la dose journalière recommandée.Réservé à l'adulte. Déconseillé aux femmes enceintes ou allaitantes, aux personnes sous traitement antidiabétique ou souffrant de problèmes cardiaques ou hépatiques et aux personnes sous traitement médicamenteux Contient de la caféine (environ 50 mg par portion journalière)En cas de doute, consulter un professionnel de santé.A conserver dans un endroit frais, sec, aéré et à l'abri de la lumière
Regulatory points
- Conditions légales
Contains tea (Camellia sinensis). Green tea extracts must provide less than 800 mg of epigallocatechin-3-gallate per daily portion, with mandatory warnings.
Source: Regulation (EC) No 1925/2006, latest consolidated version, annexe III, partie B (règlement (UE) 2022/2340).
- Conditions légales
Camellia sinensis (L.) Kuntze: Seules sont admises la poudre issue du broyage des feuilles et les préparations obtenues à partir des solvants suivants : l'eau, l'alcool à 25 % (v/v), ainsi que les solvants autorisés pour la décaféination ou la suppression des matières irritantes et amères. Les recommandations d'emploi ne doivent pas conduire à une ingestion quotidienne d'EGCG supérieure à 300 mg. L'étiquetage doit comporter des avertissements déconseillant leur prise en dehors des repas, ainsi que leur consommation par les enfants, les adolescents, les femmes enceintes ou allaitantes.
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Zingiber officinale Roscoe
Read the warning, when it applies and the studies cited
GINGER - ZINGIBER OFFICINALE
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
- Capsicum annuum L.
Read the warning, when it applies and the studies cited
CAYENNE - CAPSICUM ANNUUM Oral
Cautions and warnings
Condition of application: All products.
Keep out of the reach of children. If overdose or accidental ingestion occurs, call a poison control centre or get medical help right away (CPS 2008).
Sources cited by Health Canada (1)
- CPS 2008: Repchinksy C, Welbanks L, Bhalla A, Fortin K, Jarvis B, Jovaisas B, Acharya S. Compendium of Pharmaceutical Specialties. Ottawa (ON): Canadian Pharmacists Association; 2008.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Bradley 2006; Boon and Smith 2004).
Sources cited by Health Canada (2)
- Boon H, Smith MJ. The Complete Natural Medicine Guide to the 50 Most Common Medicinal Herbs, 2nd edition. Toronto (ON): Robert Rose Inc; 2004.
- Bradley PR, editor. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 2. Bournemouth (GB): British Herbal Medicine Association; 2006.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have stomach ulcers or inflammation (Brinker 2010).
Sources cited by Health Canada (1)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
Condition of application: Digestion; Peripheral circulation.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Health Canada monograph dated 27 March 2026
CAYENNE - CAPSICUM ANNUUM/CAPSAICIN Topical
Cautions and warnings
Condition of application: All products.
For external use only (US FDA 2023).
Sources cited by Health Canada (1)
- US FDA 2023: United States Food and Drug Administration. Over-the-Counter Monograph M017: External Analgesics Drug Products for Over-the-Counter Human Use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services. [Accessed 2026 February 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/omuf/monographs/OTC%20Monograph_M017-External%20Analgesic%20Drug%20Products%20for%20OTC%20Human%20Use%2005.02.2023.pdf
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
When using this product avoid contact with the eyes and mucous membranes. If contact occurs, rinse thoroughly with water (US FDA 2023).
Sources cited by Health Canada (1)
- US FDA 2023: United States Food and Drug Administration. Over-the-Counter Monograph M017: External Analgesics Drug Products for Over-the-Counter Human Use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services. [Accessed 2026 February 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/omuf/monographs/OTC%20Monograph_M017-External%20Analgesic%20Drug%20Products%20for%20OTC%20Human%20Use%2005.02.2023.pdf
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist, worsen, or re-occur within a few days (US FDA 2023).
Sources cited by Health Canada (1)
- US FDA 2023: United States Food and Drug Administration. Over-the-Counter Monograph M017: External Analgesics Drug Products for Over-the-Counter Human Use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services. [Accessed 2026 February 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/omuf/monographs/OTC%20Monograph_M017-External%20Analgesic%20Drug%20Products%20for%20OTC%20Human%20Use%2005.02.2023.pdf
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Keep out of the reach of children. If swallowed, call a poison control centre or get medical help right away (CPS 2008).
Sources cited by Health Canada (1)
- CPS 2008: Repchinksy C, Welbanks L, Bhalla A, Fortin K, Jarvis B, Jovaisas B, Acharya S. Compendium of Pharmaceutical Specialties. Ottawa (ON): Canadian Pharmacists Association; 2008.
Known adverse reactions
Condition of application: All products.
Stop use if headache, redness, rashes, burning discomfort and/or hypersensitivity occur (Brayfield and Cadart 2024; Zhang et al. 2008; Hoffman 2003; APhA 2002; McCleane 2000).
Sources cited by Health Canada (5)
- APhA 2002: Berardi RR, DeSimone EM, Newton GGD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. Handbook of Nonprescription Drugs: An interactive approach to self-care. 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
- Brayfield A, Cadart C, editors. Martindale: The Complete Drug Reference. London (GB): Pharmaceutical Press; 2024. [Accessed 2024 August 14]. Available from: https://www.medicinescomplete.com/#/browse/martindale
- Hoffman D. Medical Herbalism: The Science and Practice of Herbal Medicine. Rochester (VT): Healing Arts Press; 2003.
- McCleane G. Topical application of doxepin hydrochloride, capsaicin and a combination of both produces analgesia in chronic human neuropathic pain: a randomized, double-blind, placebo-controlled study. British Journal of Clinical Pharmacology 2000;49:574-579. PubMed Randomised trial
- Zhang W, Moskowitz, RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis and Cartilage 2008;16:137-162. PubMed Systematic review
- Tyrosine
Read the warning, when it applies and the studies cited
L-TYROSINE
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
Other declarations with the same name
This name is used by more than 10 declarations from different companies, so it does not identify one product. See every declaration with this name.
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.